Report cover image

Chemotheraphy-induced Nausea and Vomitting Treatment Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 129 Pages
SKU # APRC20352393

Description

Summary

According to APO Research, The global Chemotheraphy-induced Nausea and Vomitting Treatment market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Chemotheraphy-induced Nausea and Vomitting Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Chemotheraphy-induced Nausea and Vomitting Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Chemotheraphy-induced Nausea and Vomitting Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Chemotheraphy-induced Nausea and Vomitting Treatment include Eisai, Merck & Co, GlaxoSmithKline, Tesaro, Orchid Healthcare, OPKO Health, Mylan Pharmaceuticals, Mundipharma and Heron Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Chemotheraphy-induced Nausea and Vomitting Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotheraphy-induced Nausea and Vomitting Treatment.
The Chemotheraphy-induced Nausea and Vomitting Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chemotheraphy-induced Nausea and Vomitting Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Company

Eisai
Merck & Co
GlaxoSmithKline
Tesaro
Orchid Healthcare
OPKO Health
Mylan Pharmaceuticals
Mundipharma
Heron Therapeutics
Helsinn
F.Hoffmann La Roche
Especificos Stendhal
Baxter Healthcare
Barr Laboratories
Aphios
Acacia Pharma
Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Type

5-HT3 Inhibitors
NK1 Inhibitors
Others
Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Application

Delayed Nausea and Vomitting Treatment
Acute Nausea and Vomitting Treatment
Anticipatory Nausea and Vomitting Treatment
Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Application

Delayed Nausea and Vomitting Treatment
Acute Nausea and Vomitting Treatment
Anticipatory Nausea and Vomitting Treatment
Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotheraphy-induced Nausea and Vomitting Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chemotheraphy-induced Nausea and Vomitting Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotheraphy-induced Nausea and Vomitting Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Chemotheraphy-induced Nausea and Vomitting Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

129 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Chemotheraphy-induced Nausea and Vomitting Treatment by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 5-HT3 Inhibitors
2.2.3 NK1 Inhibitors
2.2.4 Others
2.3 Chemotheraphy-induced Nausea and Vomitting Treatment by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Delayed Nausea and Vomitting Treatment
2.3.3 Acute Nausea and Vomitting Treatment
2.3.4 Anticipatory Nausea and Vomitting Treatment
2.4 Assumptions and Limitations
3 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Type
3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2020-2025)
3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2026-2031)
4 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Application
4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2020-2025)
4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2020-2031)
5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Region
5.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Region (2020-2025)
5.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2026-2031)
5.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
5.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
5.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
5.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
5.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue
6.1.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue (2020-2025)
6.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2020-2025)
6.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment Head Office and Area Served
6.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Players, Product Type & Application
6.5 Global Chemotheraphy-induced Nausea and Vomitting Treatment Manufacturers Established Date
6.6 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2020-2031)
7.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2020-2025)
7.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2020-2031)
8.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2020-2025)
8.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2020-2031)
9.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2020-2025)
9.4 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2020-2031)
10.2 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2020-2025)
10.4 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2020-2031)
11.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2020-2025)
11.4 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Eisai
12.1.1 Eisai Company Information
12.1.2 Eisai Business Overview
12.1.3 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.1.4 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.1.5 Eisai Recent Developments
12.2 Merck & Co
12.2.1 Merck & Co Company Information
12.2.2 Merck & Co Business Overview
12.2.3 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.2.4 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.2.5 Merck & Co Recent Developments
12.3 GlaxoSmithKline
12.3.1 GlaxoSmithKline Company Information
12.3.2 GlaxoSmithKline Business Overview
12.3.3 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.3.4 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.3.5 GlaxoSmithKline Recent Developments
12.4 Tesaro
12.4.1 Tesaro Company Information
12.4.2 Tesaro Business Overview
12.4.3 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.4.4 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.4.5 Tesaro Recent Developments
12.5 Orchid Healthcare
12.5.1 Orchid Healthcare Company Information
12.5.2 Orchid Healthcare Business Overview
12.5.3 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.5.4 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.5.5 Orchid Healthcare Recent Developments
12.6 OPKO Health
12.6.1 OPKO Health Company Information
12.6.2 OPKO Health Business Overview
12.6.3 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.6.4 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.6.5 OPKO Health Recent Developments
12.7 Mylan Pharmaceuticals
12.7.1 Mylan Pharmaceuticals Company Information
12.7.2 Mylan Pharmaceuticals Business Overview
12.7.3 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.7.4 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.7.5 Mylan Pharmaceuticals Recent Developments
12.8 Mundipharma
12.8.1 Mundipharma Company Information
12.8.2 Mundipharma Business Overview
12.8.3 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.8.4 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.8.5 Mundipharma Recent Developments
12.9 Heron Therapeutics
12.9.1 Heron Therapeutics Company Information
12.9.2 Heron Therapeutics Business Overview
12.9.3 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.9.4 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.9.5 Heron Therapeutics Recent Developments
12.10 Helsinn
12.10.1 Helsinn Company Information
12.10.2 Helsinn Business Overview
12.10.3 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.10.4 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.10.5 Helsinn Recent Developments
12.11 F.Hoffmann La Roche
12.11.1 F.Hoffmann La Roche Company Information
12.11.2 F.Hoffmann La Roche Business Overview
12.11.3 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.11.4 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.11.5 F.Hoffmann La Roche Recent Developments
12.12 Especificos Stendhal
12.12.1 Especificos Stendhal Company Information
12.12.2 Especificos Stendhal Business Overview
12.12.3 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.12.4 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.12.5 Especificos Stendhal Recent Developments
12.13 Baxter Healthcare
12.13.1 Baxter Healthcare Company Information
12.13.2 Baxter Healthcare Business Overview
12.13.3 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.13.4 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.13.5 Baxter Healthcare Recent Developments
12.14 Barr Laboratories
12.14.1 Barr Laboratories Company Information
12.14.2 Barr Laboratories Business Overview
12.14.3 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.14.4 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.14.5 Barr Laboratories Recent Developments
12.15 Aphios
12.15.1 Aphios Company Information
12.15.2 Aphios Business Overview
12.15.3 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.15.4 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.15.5 Aphios Recent Developments
12.16 Acacia Pharma
12.16.1 Acacia Pharma Company Information
12.16.2 Acacia Pharma Business Overview
12.16.3 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2020-2025)
12.16.4 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
12.16.5 Acacia Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.